Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
The present invention relates to a method of treating pulmonary arterial hypertension by administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.
1. A method of treating class I pulmonary hypertension (pulmonary arterial hypertension (PAH)), comprising administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.
2. The method of claim 1 , wherein the selective JAK2 inhibitor is a tyrphostin.
3. The method of claim 2 , wherein the tyrphostin is AG490.
4. The method of claim 1 , wherein the patient is a human.
5. The method of claim 1 , wherein the JAK2 inhibitor is administered in a total daily dosage of about 3 mg/kg/day.
6. A method of reducing the occurrence of pulmonary arteriolar obstruction in a patient afflicted with class I pulmonary hypertension, comprising administering an effective amount of a selective JAK2 inhibitor to the patient.
7. The method of claim 6 , wherein the JAK2 inhibitor is a tyrphostin.
8. The method of claim 7 , wherein the tyrphostin is AG490.
9. The method of claim 6 , wherein the patient is a human.
10. The method of claim 6 , wherein the JAK2 inhibitor is administered in a total daily dosage of about 3 mg/kg/day.
11. The method of claim 6 , wherein the JAK2 inhibitor is administered orally, by inhalation, intravenously, subcutaneously, transdermally, or intraperitoneally.
12. The method of claim 1 , wherein the selective inhibitor of JAK2 inhibits JAK2 activity at least 2-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
13. The method of claim 1 , wherein the selective inhibitor of JAK2 inhibits JAK2 activity at least 5-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
14. The method of claim 1 , wherein the selective inhibitor of JAK2 inhibits JAK2 activity at least 10-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
15. The method of claim 1 , wherein the JAK2 inhibitor is contained within or attached to an implant.
16. The method of claim 1 , wherein the pulmonary arterial hypertension is associated with hereditary hemorrhagic telangiectasia, congenital heart disease, familial primary pulmonary hypertension, idiopathic pulmonary arterial hypertension, splenectomy, HIV infection, a collagen vascular disorder, scleroderma, mixed connective tissue disease, systemic lupus erythematosus, chronic thromboembolic pulmonary artery hypertension (distal or inoperable), toxins, anorexigens, liver disease, liver disease caused by hepatitis C or liver disease associated with portal hypertension.
17. The method of claim 6 , wherein the JAK2 inhibitor inhibits JAK2 activity at least 2-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
18. The method of claim 6 , wherein the JAK2 inhibitor inhibits JAK2 activity at least 5-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
19. The method of claim 6 , wherein the JAK2 inhibitor inhibits JAK2 activity at least 10-fold more than it inhibits JAK1, JAK3 or TYK2 activity.
20. The method of claim 6 wherein the JAK2 inhibitor is contained within or attached to an implant.